RENATA GONDIM MEIRA VELAME DE AZEVEDO

Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • conferenceObject
    Tolerability of modified gemcitabine/docetaxel (split-dose) in patients with advanced soft tissue sarcomas
    (2016) AZEVEDO, R. G. M. V. D.; FRAILE, N.; SAADI NETO, E.; LOPEZ, R. V. M.; TOLOI, D.; HOFF, P. M.; FEHER, O.; CAMARGO, V. P. D.; MUNHOZ, R.
  • article 10 Citação(ões) na Scopus
    Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis
    (2018) BONADIO, Renata Rodrigues da Cunha Colombo; AZEVEDO, Renata Gondim Meira Velame; HARADA, Guilherme; COSTA, Samantha Cabral Severino da; MIRANDA, Vanessa Costa; FREITAS, Daniela de; ABDO FILHO, Elias; FERREIRA, Patricia Alves de Oliveira; GABRIELLI, Flavia; DIZ, Maria del Pilar Estevez
    Purpose The best adjuvant treatment in high-risk endometrial cancer remains unclear. Although adjuvant chemotherapy seems to improve overall survival (OS) in locally advanced disease, the role of adding radiotherapy is not certain. We evaluated the outcomes of patients with high-risk endometrial cancer treated with adjuvant chemotherapy followed by radiotherapy. Patients and Methods We performed a retrospective analysis of patients with high-risk endometrial cancer (endometrioid histology stages III to IVA or carcinosarcoma, clear cell, or serous histology stages I to IVA) treated with adjuvant carboplatin and paclitaxel, followed by radiotherapy, from 2010 to 2017 at a Brazilian cancer center. The Kaplan-Meier method was used for survival analysis, and prognostic factors were analyzed using the Cox proportional hazards model. Results One hundred forty-six consecutive patients were evaluated. The OS rates were 86.2% at 3 years and 75.4% at 5 years. OS was significantly affected by pelvic lymphadenectomy (P = .001) and positive peritoneal cytology (P < .001). Three- and 5-year disease-free survival (DFS) rates were 78.3% and 69.5%, respectively. The initial site of recurrence was limited to the pelvis in 4.1% of patients, within the abdomen in 1.3%, and extra-abdominal in 11.6%. Patients with grade 1 or 2 endometrioid carcinoma had better prognosis than patients with endometrioid carcinoma grade 3 or nonendometrioid histology (3-year DFS, 93.67% v 68.5%, respectively; P = .0017). Conclusion Adjuvant carboplatin and paclitaxel, followed by radiotherapy, is effective in high-risk endometrial cancer and associated with low rates of pelvic recurrence, which might be explained by the addition of radiotherapy. The high-risk group is heterogeneous, and the benefit of adjuvant treatment in patients with grade 1 or 2 endometrioid carcinoma is less clear. (C) 2018 by American Society of Clinical Oncology
  • conferenceObject
    Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy in high-risk endometrial cancer: A retrospective analysis.
    (2017) BONADIO, Renata Rodrigues da Cunha Colombo; AZEVEDO, Renata Gondim Meira Velame; HARADA, Guilherme; COSTA, Samantha Cabral Severino da; MIRANDA, Vanessa Costa; FREITAS, Daniela de; FILHO, Elias Abdo; FERREIRA, Patricia Alves de Oliveira; GABRIELLI, Flavia; ESTEVEZ-DIZ, Maria Del Pilar
  • conferenceObject
    Does chemotherapy work in reversal of malignant obstruction due to gastric cancer?
    (2017) SANTOS, Vanessa Montes; AZEVEDO, Renata Gondim Meira Velame; LOPEZ, Rossana Veronica Mendoza; HOFF, Paulo Marcelo; SABBAGA, Jorge; GLASBERG, Joao
  • article 21 Citação(ões) na Scopus
    Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer
    (2018) SILVA, Saulo Brito; PEREIRA, Allan Andresson Lima; MARTA, Gustavo Nader; LIMA, Kennya Medeiros Lopes de Barros; FREITAS, Thiago Brasileiro de; MATUTINO, Adriana Reis Brandao; SOUZA, Manoel Carlos Leonardi de Azevedo; AZEVEDO, Renata Gondim Meira Velame de; VIVEIROS, Pedro Antonio Hermida de; LIMA, Julianne Maria da Silva; FILASSI, Jose Roberto; CARVALHO, Heloisa de Andrade; PIATO, Jose Roberto Morales; MANO, Max S.
    Background: and Purpose: Post-operative radiation therapy (PORT) is usually indicated for patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC) and surgery. However, the optimal timing to initiation of PORT is currently unknown. Material and methods: We retrospectively evaluated data from patients with BC who received PORT after NAC and surgery at our institution from 2008 to 2014. Patients were categorized into three groups according to the time between surgery and PORT: < 8 weeks, 8-16 weeks and > 16 weeks. Results: A total of 581 patients were included; 74% had clinical stage III. Forty-three patients started PORT within 8 weeks, 354 between 8 and 16 weeks and 184 beyond 16 weeks from surgery. With a median follow-up of 32 months, initiation of PORT up to 8 weeks after surgery was associated with better disease-free survival (DFS) (< 8 weeks versus 8-16 weeks: HR 0.33; 95% CI 0.13-0.81; p = 0.02; < 8 weeks versus > 16 weeks: HR 0.38; 95% CI 0.15-0.96; p = 0.04) and better overall survival (OS) (< 8 weeks versus 8-16 weeks: HR 0.22; 95% CI 0.05-0.90; p = 0.036; < 8 weeks versus > 16 weeks: HR 0.28; 95% CI 0.07-1.15; p = 0.08). Conclusion: PORT started up to 8 weeks after surgery was associated with better DFS and OS in locally-advanced BC patients submitted to NAC. Our findings suggest that early initiation of PORT is critically important for these patients. However, the low numbers of patients and events in this study prevent us from drawing firm conclusions.